SCHEMBL12281874

SCHEMBL12281874

COc1ccc(COc2ccc(/C(=C(\CCI)c3ccccc3)c3ccc(O)cc3)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 13/20 0.53
▸ CYP19A1 P11511 7/20 0.53
▸ ESR2 Q92731 6/20 0.53
▸ NPC1 O15118 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ESRRG P62508 5/20 0.51
▸ ESRRB O95718 3/20 0.50
▸ FFAR1 O14842 1/20 0.50
▸ CYP1A2 P05177 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2A6 P11509 1/20 0.49
▸ CYP3A5 P20815 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ PTGS1 P23219 1/20 0.49
▸ SLC6A2 P23975 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ PTGS2 P35354 1/20 0.49
▸ SLC6A3 Q01959 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12284881 0.88 ESR1 (0.65) ESR1CYP19A1ESR2NPC1POLB
SCHEMBL12134458 0.86 CYP19A1 (0.67) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL8366276 0.80 ESR1 (0.67) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL8366275 0.80 ESR1 (0.67) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL9097507 0.80 ESR1 (0.67) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL12468690 0.78 CYP19A1 (0.73) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL8364894 0.78 ESR1 (0.65) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL8364891 0.78 ESR1 (0.65) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL641723 0.78 CYP19A1 (0.73) ESR1CYP19A1ESR2ESRRGESRRB
SCHEMBL641722 0.78 CYP19A1 (0.73) ESR1CYP19A1ESR2ESRRGESRRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011129837-A1 USE OF A 4-HYDROXYTOREMIFENE PRODRUG FOR TREATMENT OF BREAST CANCER OLEMA PHARMACEUTICALS, INC. (US) 2011-10-20 — — WO disclosed
Send feedback